Literature DB >> 23774441

In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.

D F Sahm1, J Deane, C M Pillar, P Fernandes.   

Abstract

Clinical development of CEM-102 (fusidic acid) has recently begun in the United States for chronic oral treatment of prosthetic joint infections. To support this development, the in vitro activity of fusidic acid against important Staphylococcus aureus clones and resistance phenotypes was determined. Against 51 such isolates, the modal fusidic acid MIC was 0.12 μg/ml (range, 0.06 to 0.25 μg/ml for 49 isolates). This level of in vitro fusidic acid activity underscores the potential clinical utility of this compound in the United States.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23774441      PMCID： PMC3754304          DOI： 10.1128/AAC.00206-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Fusidic acid resistance in Staphylococcus aureus isolates.

Authors:  Erwin M Brown; Paul Thomas
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

2.  Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.

Authors:  M K Hayden; K Rezai; R A Hayes; K Lolans; J P Quinn; R A Weinstein
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.

Authors:  Gracia Morales; Juan J Picazo; Elvira Baos; Francisco J Candel; Ana Arribi; Beatriz Peláez; Raquel Andrade; María-Angeles de la Torre; José Fereres; Miguel Sánchez-García
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

5.  Genetic basis of resistance to fusidic acid in staphylococci.

Authors:  A J O'Neill; F McLaws; G Kahlmeter; A S Henriksen; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

6.  A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.

Authors:  J Carl Craft; Susan R Moriarty; Kay Clark; Drusilla Scott; Thorsten P Degenhardt; J Gordon Still; G Ralph Corey; Anita Das; Prabhavathi Fernandes
Journal:  Clin Infect Dis       Date:  2011-06       Impact factor: 9.079

7.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586

Review 8.  Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.

Authors:  George Sakoulas; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

9.  Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus.

Authors:  A J O'Neill; A R Larsen; R Skov; A S Henriksen; I Chopra
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

10.  Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.

Authors:  Michael A Pfaller; Mariana Castanheira; Helio S Sader; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2009-12-29       Impact factor: 5.283
View more
  3 in total

Review 1.  Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.

Authors:  Prabhavathi Fernandes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

2.  Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.

Authors:  Wafi Siala; Hector Rodriguez-Villalobos; Prabhavathi Fernandes; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.

Authors:  Mehdi Goudarzi; Bahareh Hajikhani; Sareh Kakavandi; Sana Amini; Samira Zamani; Alex van Belkum; Hossein Goudarzi; Masoud Dadashi
Journal:  Antimicrob Resist Infect Control       Date:  2021-05-01       Impact factor: 6.454
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.